Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Positron Emission Tomography01:29

Positron Emission Tomography

4.0K
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
4.0K
Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

86
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
86
Radiological Investigation III: Pulmonary Angiogram and PET Scan01:13

Radiological Investigation III: Pulmonary Angiogram and PET Scan

86
Radiological investigations are paramount in the diagnosis and management of various pulmonary diseases. Two essential investigations are the Pulmonary Angiogram and the Positron Emission Tomography (PET) Scan.
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...
86

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Acceptability of Covid-19 self-testing among Primary Health Care users.

Revista de saude publica·2026
Same author

Emapalumab's role in a severe and treatment-resistant paediatric macrophage activation syndrome.

ARP rheumatology·2026
Same author

Examination of Coligands in Mefloquine-Metal Complexes Reveals the Structural Determinants of Activity against <i>Plasmodium falciparum</i> and <i>Schistosoma mansoni</i>.

Journal of medicinal chemistry·2026
Same author

Response of male and female mice to chronic alcohol use before and during cancer.

Alcohol (Fayetteville, N.Y.)·2026
Same author

Insights from PSMAfore: impact on health-related quality of life.

Translational andrology and urology·2026
Same author

Assessing therapeutic response to Radium-223.

Seminars in nuclear medicine·2025

Related Experiment Video

Updated: Jun 6, 2025

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
09:49

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

9.9K

Theranostics Nuclear Medicine in Prostate Cancer.

Helena Lima1, Marina Etchebehere2, Mateos Bogoni3,4

  • 1Faculdade de Medicina, Pontifícia Universidade Católica de Campinas (PUCC), Campinas 13087-571, Brazil.

Pharmaceuticals (Basel, Switzerland)
|November 27, 2024
PubMed
Summary

Theranostic Nuclear Medicine combines diagnostic and therapeutic radioisotopes for diseases like prostate cancer. This approach uses imaging to guide targeted radiopharmaceutical treatments, improving patient outcomes.

Keywords:
177Lu-PSMA18F-FDG18F-fluoridePET/CTPSMARa-223nuclear medicine

More Related Videos

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.2K
Hyperpolarized 13C Metabolic Magnetic Resonance Spectroscopy and Imaging
11:43

Hyperpolarized 13C Metabolic Magnetic Resonance Spectroscopy and Imaging

Published on: December 30, 2016

10.4K

Related Experiment Videos

Last Updated: Jun 6, 2025

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
09:49

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

9.9K
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.2K
Hyperpolarized 13C Metabolic Magnetic Resonance Spectroscopy and Imaging
11:43

Hyperpolarized 13C Metabolic Magnetic Resonance Spectroscopy and Imaging

Published on: December 30, 2016

10.4K

Area of Science:

  • Nuclear Medicine
  • Oncology
  • Radiopharmaceutical Therapy

Background:

  • Theranostic Nuclear Medicine integrates diagnostic and therapeutic applications of radiopharmaceuticals.
  • The concept originated in the 1940s with radioactive iodine for thyroid conditions.
  • Its application has expanded to prevalent diseases, including prostate cancer.

Purpose of the Study:

  • To review the role of Theranostic Nuclear Medicine in prostate cancer management.
  • To discuss key diagnostic imaging modalities used in this field.
  • To correlate diagnostic imaging with corresponding therapeutic radiopharmaceuticals.

Main Methods:

  • Review of existing literature on theranostic nuclear medicine in prostate cancer.
  • Analysis of diagnostic imaging techniques (e.g., bone scintigraphy).
  • Examination of therapeutic radiopharmaceuticals used in conjunction with imaging.

Main Results:

  • Theranostic Nuclear Medicine enables precise assessment and targeted treatment of prostate cancer.
  • Diagnostic imaging identifies disease extent, guiding the selection of therapeutic agents.
  • Radiopharmaceuticals can alleviate pain and potentially improve survival in metastatic prostate cancer.

Conclusions:

  • Theranostic Nuclear Medicine offers a personalized approach to prostate cancer treatment.
  • The integration of diagnostic and therapeutic nuclear medicine is crucial for effective management.
  • Further advancements in theranostic applications hold promise for improved prostate cancer care.